Medline (MDLN)
Integrates medical-surgical products, third-party distribution, logistics, and clinical implementation support.
$34.19
vs last close−0.24 (−0.70%)
In millions of USD, except per-share figures
| In millions | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6,185 | 6,388 | 6,644 | 6,886 | 7,115 | 7,787 | 7,352 | 7,685 |
| Cost of revenue | 4,691 | 4,804 | 4,995 | 5,157 | 5,417 | 5,873 | 5,687 | 5,470 |
| Gross profit | 1,494 | 1,584 | 1,649 | 1,729 | 1,698 | 1,914 | 1,665 | 2,215 |
| 978 | 1,010 | 1,058 | 1,100 | 1,124 | 1,489 | 1,243 | 1,820 | |
| Selling, general & administrative | 976 | 988 | 1,100 | 1,086 | 1,116 | 1,265 | 1,228 | 1,295 |
| Other expenses | 2 | 22 | −42 | 14 | 8 | 224 | 15 | 525 |
| Operating income | 516 | 574 | 591 | 629 | 574 | 425 | 422 | 395 |
| −216 | −236 | −253 | −270 | −229 | −219 | −131 | −160 | |
| Interest income | 75 | 73 | 34 | 30 | 35 | 0 | 29 | 49 |
| Interest expense | 267 | 174 | 214 | 233 | 228 | 166 | 165 | 168 |
| Other non-operating income | −51 | 62 | 39 | 37 | 1 | 219 | −5 | −8 |
| Income before tax | 300 | 338 | 338 | 359 | 345 | 206 | 291 | 235 |
| Income tax expense | 8 | 14 | 16 | 26 | 23 | 26 | 52 | 96 |
| Net income from continuing operations | 292 | 324 | 322 | 333 | 322 | 180 | 239 | 139 |
| Net income | 292 | 324 | 322 | 333 | 322 | 180 | 129 | 60 |
| EPS, basic | $0.37 | $0.41 | $0.40 | $0.42 | $0.41 | $0.22 | $0.16 | $0.07 |
| EPS, diluted | $0.37 | $0.41 | $0.40 | $0.42 | $0.41 | $0.22 | $0.16 | $0.07 |
| Weighted average shares, basic | 787 | 787 | 800 | 787 | 787 | 812 | 819 | 857 |
| Weighted average shares, diluted | 787 | 787 | 800 | 787 | 787 | 812 | 825 | 861 |
| EBITDA | 806 | 760 | 799 | 842 | 826 | 382 | 681 | 659 |
| Depreciation & amortization | 239 | 248 | 247 | 250 | 253 | 176 | 254 | 256 |
| EBIT | 567 | 512 | 552 | 592 | 573 | 206 | 427 | 403 |